. 2019 Jul 15;5(3):00004-2019. doi: 10.1183/23120541.00004-2019

TABLE 2.

Target and organ at risk doses

	EBUS-upstaged^#		EBUS-downstaged^¶
	EBUS-TBNA+PET	PET	EBUS-TBNA+PET	PET
PTV D95% Gy	58.1±2.7	16.3±3.3	59.7±0.6	58.6±1.1
Mean heart Gy	10.9±7.9	8.4±7.4	12.2±3.5	15.9±8.4
Mean oesophagus Gy	18.5±5.6	12.0±5.7	16.6±10.4	29.1±5.2
Lung NTCP %	9.6±2.0	7.6±1.5	12.6±5.3	18.3±5.3

Data are presented as mean±sd. EBUS: endobronchial ultrasound; TBNA: transbronchial needle aspiration; PET: positron emission tomography; PTV: planning target volume; D95%: treatment volume receiving >95% of planned dose; NTCP: normal tissue complication probability. ^#: EBUS-positive/PET-negative, n=4, dose was changed; ^¶: EBUS-negative/PET-positive, n=4 (because two out of six patients where EBUS identified a lesser extent of lymph node disease could not reasonably be encompassed within a radical radiotherapy field when planned based on PET alone and therefore plans were not created), potential change in dose.